Efficacy of desvenlafaxine succinate for menopausal hot flashes

Introduction: The concern for the development of breast cancer, stroke, cardiovascular disease and deep venous thrombosis with the use of hormonal therapy has led to the development of alternative nonhormonal forms of therapy like desvenlafaxine for the management of hot flashes. Areas covered: This review is based upon a PubMed search and clinical trials. The pharmacokinetics and pharmacodynamics of desvenlafaxine are reviewed. This review outlines the effects of desvenlafaxine in management of severity and frequency of vasomotor symptoms, sleep quality and quality of life in postmenopausal women. The potential adverse effects of desvenlafaxine are summarized. Expert opinion: Based on the evidence from randomized clinical trials, desvenlafaxine is an alternate viable option for reducing the frequency and severity of hot flashes when other treatments fail. In clinical trials, it has been shown that desvenlafaxine reduced the frequency of hot flashes by 55 – 69%. In the trials so far it appears to have good safety and tolerability profile when the drug is initiated in titrating doses. The optimum dose is 100 mg/day and is to be started at 50 mg/day for 3 days and titrated to 100 mg/day. The most common adverse events reported were nausea, dry mouth, fatigue, constipation, diarrhea and somnolence.

[1]  Lauren Weber,et al.  ParoXetine: A First for Selective Serotonin Reuptake Inhibitors – a New Use: Approved for Vasomotor Symptoms in Postmenopausal Women , 2014, Women's health.

[2]  J. Gallagher,et al.  Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause , 2013, Expert opinion on pharmacotherapy.

[3]  J. Simon,et al.  Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials , 2013, Menopause.

[4]  M. Yadav,et al.  Potential role of gabapentin and extended-release gabapentin in the management of menopausal hot flashes , 2013, International journal of general medicine.

[5]  Zheng Sun,et al.  Efficacy and Safety of Desvenlafaxine Treatment for Hot Flashes Associated with Menopause: A Meta-Analysis of Randomized Controlled Trials , 2013, Gynecologic and Obstetric Investigation.

[6]  G. Constantine,et al.  Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial , 2013, Menopause.

[7]  D. Archer,et al.  Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial , 2012, Menopause.

[8]  D. Archer,et al.  Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause , 2012, Menopause.

[9]  D. Archer,et al.  Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms , 2012, Climacteric : the journal of the International Menopause Society.

[10]  Daniel J Buysse,et al.  Sleep is associated with the metabolic syndrome in a multi-ethnic cohort of midlife women: the SWAN Sleep Study. , 2012, Sleep.

[11]  N. Panay,et al.  Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms , 2012, Climacteric : the journal of the International Menopause Society.

[12]  J. Gallagher,et al.  The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause. , 2012, Journal of women's health.

[13]  H. Kravitz,et al.  Sleep during the perimenopause: a SWAN story. , 2011, Obstetrics and gynecology clinics of North America.

[14]  A. LaCroix,et al.  Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. , 2011, JAMA.

[15]  J. Posener,et al.  The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment. , 2011, International journal of clinical pharmacology and therapeutics.

[16]  N. Woods,et al.  Sleep symptoms during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study. , 2010, Sleep.

[17]  C. Loprinzi,et al.  Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  G. Constantine,et al.  Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. , 2009, American journal of obstetrics and gynecology.

[19]  G. Constantine,et al.  A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. , 2009, American journal of obstetrics and gynecology.

[20]  N. Santoro.  Symptoms of menopause: hot flushes. , 2008, Clinical obstetrics and gynecology.

[21]  L. Holmberg,et al.  Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. , 2008, Journal of the National Cancer Institute.

[22]  G. Constantine,et al.  Efficacy and Tolerability of Desvenlafaxine Succinate Treatment for Menopausal Vasomotor Symptoms: A Randomized Controlled Trial , 2008, Obstetrics and gynecology.

[23]  S. Crawford,et al.  Relation of Daily Urinary Hormone Patterns to Vasomotor Symptoms in a Racially/Ethnically Diverse Sample of Midlife Women: Study of Women's Health Across the Nation , 2007, Reproductive Sciences.

[24]  A. Kiss,et al.  A randomized controlled trial of the effect of dietary soy and flaxseed muffins on quality of life and hot flashes during menopause , 2006, Menopause.

[25]  T. Roehrs,et al.  Effects of REM sleep and ambient temperature on hot flash-induced sleep disturbance , 2006, Menopause.

[26]  K. Matthews,et al.  Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. , 2006, American journal of public health.

[27]  M. Ohayon.  Severe hot flashes are associated with chronic insomnia. , 2006, Archives of internal medicine.

[28]  Rongwei Fu,et al.  Management of Miscarriage: Expectant, Medical, or Surgical? Results of Randomised Controlled Trial (Miscarriage Treatment [MIST] Trial) , 2006, Annals of internal medicine.

[29]  A. Patat,et al.  PI‐73 , 2006 .

[30]  R. Freedman.  Pathophysiology and treatment of menopausal hot flashes. , 2005, Seminars in reproductive medicine.

[31]  A. Patat,et al.  Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ascending single doses of desvenlafaxine (DVS‐233 SR) in healthy subjects , 2005 .

[32]  D. Raible,et al.  An open‐label, randomized, single‐dose, dose‐proportionality study of oral doses of a sustained‐release formulation of desvenlafaxine succinate in healthy subjects , 2005 .

[33]  L. Richards,et al.  The absolute bioavailability of an oral sustained‐release formulation of desvenlafaxine succinate in healthy subjects , 2005 .

[34]  J. Paul,et al.  An ascending multiple‐dose study of the safety and pharmacokinetics of a sustained‐release formulation of desvenlafaxine succinate in healthy subjects , 2005 .

[35]  T. Lawrence,et al.  No effect of concomitant administration of nebivolol and losartan in healthy volunteers genotyped for CYP2D6 status , 2005 .

[36]  K. Matthews,et al.  The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition. , 2004, The Journal of clinical endocrinology and metabolism.

[37]  National Institutes of Health State-of-the-Science Conference Statement: Management of Menopause-Related Symptoms , 2005, Annals of Internal Medicine.

[38]  T. Roehrs,et al.  Lack of sleep disturbance from menopausal hot flashes. , 2004, Fertility and sterility.

[39]  D. Archer,et al.  Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. , 2003, Menopause.

[40]  A. Fugh-Berman,et al.  Complementary and Alternative Medicine for Menopausal Symptoms: A Review of Randomized, Controlled Trials , 2002, Annals of Internal Medicine.

[41]  T. Shanafelt,et al.  Pathophysiology and treatment of hot flashes. , 2002, Mayo Clinic proceedings.

[42]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[43]  E. Perez,et al.  Phase III evaluation of fluoxetine for treatment of hot flashes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  A. Maclennan,et al.  Oral oestrogen replacement therapy versus placebo for hot flushes. , 2001, The Cochrane database of systematic reviews.

[45]  J. Lenihan,et al.  Initial 17β‐Estradiol Dose for Treating Vasomotor Symptoms , 2000, Obstetrics and gynecology.

[46]  C. Eap,et al.  Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report. , 2000, Pharmacopsychiatry.

[47]  William L. Haskell,et al.  Potential Health Benefits of Dietary Phytoestrogens: A Review of the Clinical, Epidemiological, and Mechanistic Evidence1 , 1998 .

[48]  C D Gardner,et al.  Clinical review 97: Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. , 1998, The Journal of clinical endocrinology and metabolism.

[49]  K. McPherson,et al.  Measuring the impact of menopausal symptoms on quality of life. , 1993, BMJ.

[50]  Fredi Kronenberg,et al.  Hot Flashes: Epidemiology and Physiologya , 1990, Annals of the New York Academy of Sciences.

[51]  F Kronenberg,et al.  Hot flashes: epidemiology and physiology. , 1990, Annals of the New York Academy of Sciences.

[52]  P. Fioretti,et al.  Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women , 1988, Obstetrics and gynecology.

[53]  J. Ubachs,et al.  Effect of Bellergal Retard on climacteric complaints: a double-blind, placebo-controlled study. , 1987, Maturitas.

[54]  M. Hammond,et al.  A double blind study to evaluate the effect of methyldopa on menopausal vasomotor flushes. , 1984, The Journal of clinical endocrinology and metabolism.